InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,143.60
(
0.64%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.04
(
0.29%
)
Bitcoin
68,893.93
(
1.69%
)
Post# of 285918
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

ktcougar

Send PM Follow Ignore
Followers 38
Posts 7208
Boards Moderated 1
Alias Born 03/06/2003

ktcougar

Re: SSP post# 280152

Tuesday, 07/27/2021 6:09:13 AM

Tuesday, July 27, 2021 6:09:13 AM

Post# of 285918
OBSV over $3 in the PM:

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
https://finance.yahoo.com/news/organon-obseva-enter-global-license-050000070.html

Under the terms of the agreement, Organon will gain exclusive worldwide rights to develop and commercialize ebopiprant. ObsEva is entitled to receive tiered double-digit royalties on commercial sales as well as up to $500 million in upfront and milestone payments including $25 million to be paid at signing, up to $90 million in development and regulatory milestones and up to $385 million sales based milestones. Goldman Sachs acted as exclusive financial advisor to ObsEva.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up